While previous candidate gene studies of common genetic variants linked PPARGC1A with ovarian cancer and familial breast cancer risk [34,35], our WGS study, focusing on rare and functional variants, was the first to reveal the effect of PPARGC1A in the context of BRCA1/2 mutation. This evidence concerns the gene BRCA1 and ovarian carcinoma.